Anti-schizophrenia drug Cobenfy could treat Alzheimer's
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, USA, on Wednesday, December 27, 2023.…
biogen inc
Innovative biotech stocks have a good chance of breaking out in 2025
The trends may be turning in favor of biotech stocks in 2025 after several years of poor performance, but it…
Biogen (BIIB) Third Quarter 2024 Earnings
A test tube is seen in front of the Biogen logo in this illustration taken on December 1, 2021. Ruvic…
GE Healthcare has been an under-the-radar winner and a new catalyst has just arrived
GE Healthcare's quiet outperformance is becoming harder to ignore, and its new drug used in radiology to improve the diagnosis…
Biogen (BIIB) Q2 2024 Results
Biogen The company on Thursday reported second-quarter earnings and revenue, which beat estimates and raised its full-year guidance as the…
GEHC gives reasons to look beyond China's temporary woes and stocks rise again
GE Healthcare reported a mixed second quarter on Wednesday morning, and shares initially dipped sharply. Shares then reversed higher as…
Eisai Biogen's Leqembi Alzheimer's drug shows benefits over three years
The newly FDA-approved Alzheimer's treatment, Leqembi, will be prepared at Abington Neurological Associates in Abington, Pennsylvania on Tuesday, November 7,…
Novo Nordisk's liraglutide GLP-1 may slow the progression of Alzheimer's
A box of the drug Victoza, manufactured by Novo Nordisk Pharmaceutical, sits on a pharmacy counter in Provo, Utah, January…
Biogen Eisai's Leqembi Alzheimer's drug rejected by EU regulator
European drug regulators on Friday rejected Leqembi's Alzheimer's treatment Biogen and Eisaicreating another hurdle for companies as they struggle to…
Investors could see evidence in H2 of AI's assistance in drug discovery
As investors look to the future to imagine which industries are ripe to be reshaped and energized by artificial intelligence,…